Hhlr Advisors, Ltd. Kiniksa Pharmaceuticals, Ltd. Transaction History

Hhlr Advisors, Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.63 - $21.74 $55.3 Million - $68.2 Million	3,135,735 New	3,135,735 $61.9 Million
Q2 2023 Aug 14, 2023	SELL	$10.44 - $16.48 $3.33 Million - $5.26 Million	-319,350 Reduced 31.37%	698,741 $9.84 Million
Q1 2023 May 15, 2023	SELL	$10.7 - $15.79 $17.2 Million - $25.4 Million	-1,605,833 Reduced 61.2%	1,018,091 $11 Million
Q4 2022 Feb 14, 2023	SELL	$11.42 - $17.05 $3.38 Million - $5.05 Million	-296,099 Reduced 10.14%	2,623,924 $39.3 Million
Q3 2020 Nov 16, 2020	BUY	$15.21 - $25.53 $7.24 Million - $12.2 Million	476,190 Added 19.49%	2,920,023 $44.7 Million
Q2 2020 Aug 14, 2020	BUY	$15.08 - $26.0 $8.26 Million - $14.2 Million	547,945 Added 28.9%	2,443,833 $62.3 Million
Q4 2019 Feb 14, 2020	BUY	$5.24 - $12.96 $148,113 - $366,327	28,266 Added 1.51%	1,895,888 $21 Million
Q3 2019 Nov 14, 2019	BUY	$8.15 - $15.88 $258,632 - $503,935	31,734 Added 1.73%	1,867,622 $15.9 Million
Q1 2019 May 15, 2019	BUY	$15.93 - $26.59 $7.12 Million - $11.9 Million	447,000 Added 32.18%	1,835,888 $33.2 Million
Q4 2018 Feb 14, 2019	BUY	$16.25 - $28.09 $22.6 Million - $39 Million	1,388,888 New	1,388,888 $39 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $734M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.